MCID: URT051
MIFTS: 41

Ureter, Cancer of

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Ureter, Cancer of

MalaCards integrated aliases for Ureter, Cancer of:

Name: Ureter, Cancer of 57
Ureter Carcinoma 12 55 15 73
Ureteral Benign Neoplasm 12 15
Ureteral Neoplasms 44 73
Ureter Cancer 12 15
Malignant Neoplasm of Ureter 73
Malignant Tumour of Ureter 12
Malignant Ureteral Tumor 12
Neoplasm of Ureter 12
Ureteral Carcinoma 12
Ureteral Tumor 12

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
ureter, cancer of:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 191600
Disease Ontology 12 DOID:11819 DOID:11885 DOID:4939
ICD10 33 C66
ICD9CM 35 189.2
MeSH 44 D014516
SNOMED-CT 68 94121005
MedGen 42 C0153619
SNOMED-CT via HPO 69 263681008 126882009 363458004

Summaries for Ureter, Cancer of

Disease Ontology : 12 An ureter cancer that is located in the ureter.

MalaCards based summary : Ureter, Cancer of, also known as ureter carcinoma, is related to regional ureteric cancer and ureter adenocarcinoma. An important gene associated with Ureter, Cancer of is PLAUR (Plasminogen Activator, Urokinase Receptor), and among its related pathways/superpathways are Endochondral Ossification and Lung fibrosis. The drugs Gemcitabine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include kidney, lung and liver, and related phenotypes are neoplasm of the ureter and homeostasis/metabolism

Wikipedia : 76 Ureteral cancer is cancer of the ureters, muscular tubes that propel urine from the kidneys to the... more...

Description from OMIM: 191600

Related Diseases for Ureter, Cancer of

Graphical network of the top 20 diseases related to Ureter, Cancer of:



Diseases related to Ureter, Cancer of

Symptoms & Phenotypes for Ureter, Cancer of

Symptoms via clinical synopsis from OMIM:

57
G U:
cancer of ureter


Clinical features from OMIM:

191600

Human phenotypes related to Ureter, Cancer of:

32
# Description HPO Frequency HPO Source Accession
1 neoplasm of the ureter 32 HP:0100516

MGI Mouse Phenotypes related to Ureter, Cancer of:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.63 ADRA1A ANKRD11 MGP PLAU PLAUR TERT
2 muscle MP:0005369 9.26 ADRA1A MGP PLAU PLAUR
3 respiratory system MP:0005388 8.92 MGP PLAU PLAUR TERT

Drugs & Therapeutics for Ureter, Cancer of

Drugs for Ureter, Cancer of (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 1,Phase 2 95058-81-4 60750
2
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 2767 441203 84093
3
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
4
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 241903 13342
5
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
6
Pemetrexed Approved, Investigational Phase 3,Phase 2 150399-23-8, 137281-23-3 446556 60843
7
Methylcobalamin Approved, Experimental, Investigational Phase 3,Phase 2 13422-55-4
8
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
9
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
10
Hydroxocobalamin Approved Phase 3,Phase 2 13422-51-0 11953898 44475014
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2 1177-87-3
12
Methotrexate Approved Phase 3,Phase 2 59-05-2, 1959-05-2 126941
13
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2 23214-92-8 31703
14
Bevacizumab Approved, Investigational Phase 3 216974-75-3
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
16
Cyanocobalamin Approved, Nutraceutical Phase 3,Phase 2 68-19-9 44176380
17
Cobalamin Experimental Phase 3,Phase 2 13408-78-1 6438156
18
Doxil Approved June 1999 Phase 3,Phase 1,Phase 2 31703
19 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
20 Antimetabolites Phase 3,Phase 1,Phase 2
21 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
22 Immunologic Factors Phase 3,Phase 1,Phase 2
23 Antiviral Agents Phase 3,Phase 1,Phase 2
24 Anti-Infective Agents Phase 3,Phase 1,Phase 2
25 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
26 Immunoglobulins Phase 3,Phase 2,Phase 1
27 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
28 Antibodies Phase 3,Phase 2,Phase 1
29 Antimitotic Agents Phase 3,Phase 2,Phase 1
30 Albumin-Bound Paclitaxel Phase 3,Phase 2
31 Vitamin B Complex Phase 3,Phase 2,Phase 1
32 Vitamin B9 Phase 3,Phase 2,Phase 1
33 Micronutrients Phase 3,Phase 2,Phase 1
34 Vitamins Phase 3,Phase 2,Phase 1
35 Folate Phase 3,Phase 2,Phase 1
36 Trace Elements Phase 3,Phase 2,Phase 1
37 Angiogenesis Inhibitors Phase 3,Phase 1
38 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
39 Angiogenesis Modulating Agents Phase 3,Phase 1
40 Antineoplastic Agents, Hormonal Phase 3,Phase 2
41 Vitamin B12 Phase 3,Phase 2
42
protease inhibitors Phase 3,Phase 2
43 Vitamin B 12 Phase 3,Phase 2
44 Autonomic Agents Phase 3,Phase 2
45 HIV Protease Inhibitors Phase 3,Phase 2
46 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
47 glucocorticoids Phase 3,Phase 2
48 Gastrointestinal Agents Phase 3,Phase 2
49 Antiemetics Phase 3,Phase 2
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Recruiting NCT03474107 Phase 3 enfortumab vedotin;docetaxel;vinflunine;paclitaxel
2 Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Recruiting NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
3 Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
4 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
5 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
6 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer Unknown status NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
7 Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum Completed NCT01426126 Phase 2 Genexol PM
8 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma Completed NCT01328574 Phase 2 TRC105
9 A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer Completed NCT00661609 Phase 2 AZD4877
10 Arsenic Trioxide in Treating Patients With Urothelial Cancer Completed NCT00009867 Phase 2 arsenic trioxide
11 Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Completed NCT00072150 Phase 2 bortezomib
12 Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Recruiting NCT03520231 Phase 2 Denosumab;Gemcitabine;Carboplatin;Cisplatin
13 Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma Recruiting NCT03179943 Phase 2 Atezolizumab;Guadecitabine
14 Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Recruiting NCT03617913 Phase 2 Avelumab;Cisplatin;Fluorouracil;Mitomycin
15 Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Recruiting NCT03237780 Phase 2 Atezolizumab;Eribulin Mesylate
16 Afatinib in Advanced Refractory Urothelial Cancer Recruiting NCT02122172 Phase 2 afatinib dimaleate
17 A Trial to Evaluate Pemetrexed Clinical Responses in Relation to Tumor MTAP Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma Recruiting NCT02693717 Phase 2 Pemetrexed;Dexamethasone
18 A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function Active, not recruiting NCT02665039 Phase 2 Vinflunine;Gemcitabine;Carboplatin
19 Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Active, not recruiting NCT00749892 Phase 2 Erlotinib Hydrochloride
20 Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery Active, not recruiting NCT02178241 Phase 2 Eribulin Mesylate;Gemcitabine Hydrochloride
21 Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Not yet recruiting NCT03513952 Phase 2 Atezolizumab
22 A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy Terminated NCT01234519 Phase 1, Phase 2 AEZS-108;AEZS-108 at MTD
23 DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma Terminated NCT01353222 Phase 2
24 Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer Withdrawn NCT01639521 Phase 2 cisplatin;gemcitabine hydrochloride;methotrexate;vinblastine;doxorubicin hydrochloride
25 Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies Completed NCT01182168 Phase 1 gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
26 Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors Completed NCT01352962 Phase 1 Gemcitabine;Carboplatin;Lenalidomide
27 Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract Completed NCT01844947 Phase 1 Vinflunine;Sorafenib
28 Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery Recruiting NCT02812420 Phase 1
29 A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Recruiting NCT03590054 Phase 1 Abexinostat
30 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib S-malate
31 Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer Active, not recruiting NCT02300610 Phase 1 Enzalutamide;Cisplatin;Gemcitabine
32 Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Active, not recruiting NCT00479128 Phase 1 Bortezomib;Gemcitabine;Doxorubicin
33 CLE Characteristics of Upper Urinary Tract Urothelial Carcinoma Completed NCT03013920
34 Postoperative Telerounding: A Multi-Center Prospective Randomized Assessment of Patient Outcomes and Satisfaction. Completed NCT00263107
35 Familial and Atypical Urothelial Cancer Registry Recruiting NCT00902590
36 UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch Recruiting NCT02643043
37 Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma Recruiting NCT03291028
38 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
39 Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers Active, not recruiting NCT01846520 Not Applicable

Search NIH Clinical Center for Ureter, Cancer of

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: ureteral neoplasms

Genetic Tests for Ureter, Cancer of

Anatomical Context for Ureter, Cancer of

MalaCards organs/tissues related to Ureter, Cancer of:

41
Kidney, Lung, Liver, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Ureter, Cancer of:

19
The Ureter

Publications for Ureter, Cancer of

Articles related to Ureter, Cancer of:

# Title Authors Year
1
Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter cancer. ( 24202956 )
2013
2
Papillary urothelial carcinoma in sigmoid neobladder suggesting 'intraluminal seeding' from ureter cancer. ( 19138291 )
2008
3
Concomitant occurrence of a primary renal NHL and of a papillary urothelial ureter cancer. ( 17725112 )
2007
4
The Copenhagen case-control study of renal pelvis and ureter cancer: role of analgesics. ( 2606581 )
1989
5
The Copenhagen case-control study of renal pelvis and ureter cancer: role of smoking and occupational exposures. ( 3356489 )
1988

Variations for Ureter, Cancer of

Expression for Ureter, Cancer of

Search GEO for disease gene expression data for Ureter, Cancer of.

Pathways for Ureter, Cancer of

Pathways related to Ureter, Cancer of according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.22 MGP PLAU
2 11.17 PLAU TERT
3 11.11 PLAU PLAUR
4 10.94 PLAU PLAUR
5 10.83 PLAU PLAUR
6 10.33 MGP PLAU PLAUR
7 10.07 PLAU PLAUR

GO Terms for Ureter, Cancer of

Cellular components related to Ureter, Cancer of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 specific granule membrane GO:0035579 8.62 PLAU PLAUR

Biological processes related to Ureter, Cancer of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibrinolysis GO:0042730 8.62 PLAU PLAUR

Sources for Ureter, Cancer of

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....